SRR12202409
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.480
- ANGIOGENESIS+0.350
- KRAS_SIGNALING_DN+0.350
- HYPOXIA+0.290
- MYOGENESIS+0.290
- INTERFERON_ALPHA_RESPONSE+0.250
- TNFA_SIGNALING_VIA_NFKB+0.250
- UV_RESPONSE_UP+0.250
- XENOBIOTIC_METABOLISM+0.250
- WNT_BETA_CATENIN_SIGNALING+0.220
Top 10 suppressed
- PROTEIN_SECRETION-0.450
- MYC_TARGETS_V1-0.380
- E2F_TARGETS-0.310
- G2M_CHECKPOINT-0.290
- UV_RESPONSE_DN-0.280
- MITOTIC_SPINDLE-0.270
- ANDROGEN_RESPONSE-0.210
- ALLOGRAFT_REJECTION-0.190
- KRAS_SIGNALING_UP-0.190
- TGF_BETA_SIGNALING-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG717 | — | — | 0.844 |
| 2 | SAMN03290915 | — | — | 0.795 |
| 3 | SRR8518440 | — | C | 0.781 |
| 4 | SJEPD001505_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.781 |
| 5 | TCGA-85-A4JC-01A-11R-A24Z-07 | — | cohortSQ1 | 0.781 |
| 6 | R24 | — | — | 0.755 |
| 7 | 80bea63b-bc3a-4999-8c11-a35c92183cd7 | — | — | 0.747 |
| 8 | SJEPD001521_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.742 |
| 9 | SRR1394755 | GTEX | — | 0.738 |
| 10 | c0054cf0-8f4b-47b6-a8fc-63a1fd36bcc7 | — | — | 0.737 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.480 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.350 | Remibrutinib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.250 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |